Therapy cuts risk of first heart failure event by 45% in ATTR-CM trial
Real-world studies highlight fewer hospitalizations and stable kidney health
Written by |
Attruby cut the risk of a first heart failure event by 45% in an ATTR-CM trial and outperformed Vyndamax in real-world data. (Photo from iStock)
The approved therapy Attruby (acoramidis) significantly lowered the risk of a first heart failure event in people with transthyretin amyloid cardiomyopathy (ATTR-CM), according to new data from a global, placebo-controlled clinical trial.
Attruby “reduced the risk of a first heart failure event by 45%, with separation from placebo within the first month and lower rates of every type of heart failure event we looked at,” Mazen Hanna, MD, of Cleveland Clinic, said in a press release from Bridgebio, the company that sells Attruby in the U.S. “Seeing an effect that early, and across a broad range of patients, is meaningful for a disease where time matters.”
Meanwhile, analyses from real-world studies suggest that Attruby may be better at preventing heart failure worsening than Vyndamax (tafamidis), another approved ATTR-CM treatment.
These and other findings were presented at the American Heart Association Scientific Sessions 2026 in Chicago, and the XX International Symposium on Amyloidosis 2026 in Montevideo, Uruguay.
How Attruby targets ATTR-CM
“ATTR-CM causes heart failure in our patients when misfolded transthyretin proteins build up as amyloid fibrils in the heart muscle, making the walls stiff and rigid,” Hanna said. “It is the cause of urgent doctor visits, hospital stays, and, ultimately, death, so preventing these events matters most to people with ATTR-CM, their families and their care teams.”
Attruby is an oral transthyretin stabilizer, designed to slow disease progression by preventing the protein from forming toxic clumps. It is approved in the U.S. to reduce the risk of heart-related hospitalization and death in adults with ATTR-CM.
This approval was based largely on data from the Phase 3 ATTRibute-CM clinical trial (NCT03860935), which tested the therapy against a placebo in more than 600 adults with ATTR-CM over 2.5 years. Results showed Attruby significantly reduced the risk of death or heart-related hospitalizations.
Newly presented ATTRibute-CM data, shared by Hanna, came from an analysis comparing the risk of a first heart failure event in participants given Attruby or a placebo. After 2.5 years, slightly less than half (48.2%) of participants on Attruby and about two-thirds (67.3%) of those on the placebo experienced a heart failure event.
Attruby’s superiority was seen across different types of heart failure events, including hospitalization for at least 24 hours (13% vs. 25.7%), urgent clinic or emergency visits (3.9% vs. 6.4%), outpatient worsening (40.8% vs. 59.4%), and death (9% vs. 13.9%).
Results were also consistent across patients with different New York Heart Association classes of heart failure (a standard system that rates heart failure severity based on physical symptoms) and those with different blood levels of a heart-damage marker called NT-proBNP at the trial’s start.
In addition, participants originally assigned Attruby showed a significantly lower risk, by 58%, of heart failure-related death over 4.5 years relative to those originally given the placebo and switched to Attruby when entering ATTRibute-CM’s extension portion 2.5 years later.
“This is strong validation that early treatment with [Attruby] can improve clinical outcomes,” Hanna said.
Kidney safety and real-world comparisons with Vyndamax
Additional ATTRibute-CM data examined Attruby’s impact on kidney function. In line with previous reports, results suggest that kidney function tends to dip immediately after Attruby is started, then stabilize over long-term therapy.
The new findings suggest that this pattern is observed across diverse subgroups of ATTR-CM patients, regardless of factors such as diabetes status or other medication use. Data also affirm that Attruby does not cause meaningful changes in kidney safety markers or worsening of kidney function in patients with pre-existing severe kidney disease.
In a separate presentation, researchers shared real-world medical data from German healthcare databases comparing outcomes among ATTR-CM patients who started Attruby or Vyndamax, another oral transthyretin stabilizer, for the first time from 2025 through 2026.
The analysis, including 488 patients who initiated Attruby and 659 who started Vyndamax, was led by Bayer, which markets Attruby in the European Union under the brand name Beyonttra.
Results showed that over a year of follow-up, the risk of increasing the dose of diuretic medications was significantly lower, by 23%, with Attruby than with Vyndamax. Diuretics help reduce the excess fluid that accumulates in the body in people with heart failure, and needing stronger diuretic treatment is an established early sign of worsening heart failure.
These findings are consistent with two real-world studies in the U.S., which similarly suggested better outcomes with Attruby than Vyndamax, including fewer clinical worsening events and hospitalizations.
Leave a comment
Fill in the required fields to post. Your email address will not be published.